Knut Eis

1.2k total citations
13 papers, 361 citations indexed

About

Knut Eis is a scholar working on Molecular Biology, Computational Theory and Mathematics and Pathology and Forensic Medicine. According to data from OpenAlex, Knut Eis has authored 13 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 3 papers in Computational Theory and Mathematics and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Knut Eis's work include Computational Drug Discovery Methods (3 papers), Chemical Synthesis and Analysis (2 papers) and Cancer therapeutics and mechanisms (2 papers). Knut Eis is often cited by papers focused on Computational Drug Discovery Methods (3 papers), Chemical Synthesis and Analysis (2 papers) and Cancer therapeutics and mechanisms (2 papers). Knut Eis collaborates with scholars based in Germany, United States and Norway. Knut Eis's co-authors include Hans‐Günther Schmalz, Dominik Mumberg, Volker Schulze, Oliver Geis, Gerhard Siemeister, Lars Wortmann, Remo Kranich, Manfred Husemann, Francis A. Barr and Stefan Prechtl and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Chemistry - A European Journal.

In The Last Decade

Knut Eis

13 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Knut Eis Germany 7 239 140 111 74 52 13 361
Alan Futran United States 7 228 1.0× 44 0.3× 141 1.3× 36 0.5× 54 1.0× 8 383
Mark Charles United Kingdom 8 205 0.9× 48 0.3× 247 2.2× 43 0.6× 27 0.5× 9 498
Takashi Yoshizumi Japan 9 278 1.2× 55 0.4× 125 1.1× 130 1.8× 61 1.2× 16 449
Sarah James United Kingdom 8 254 1.1× 78 0.6× 99 0.9× 29 0.4× 24 0.5× 10 372
Erik Klapproth Germany 11 119 0.5× 41 0.3× 112 1.0× 175 2.4× 38 0.7× 21 356
Lars Wortmann Germany 11 476 2.0× 159 1.1× 172 1.5× 232 3.1× 21 0.4× 18 692
Baptiste Ronan France 12 260 1.1× 99 0.7× 344 3.1× 26 0.4× 41 0.8× 13 739
Helena Posteri Italy 10 205 0.9× 64 0.5× 160 1.4× 107 1.4× 11 0.2× 12 342
Manisha Das India 9 156 0.7× 38 0.3× 81 0.7× 160 2.2× 39 0.8× 17 333
Peter F. Bousquet United States 15 300 1.3× 46 0.3× 258 2.3× 109 1.5× 14 0.3× 21 561

Countries citing papers authored by Knut Eis

Since Specialization
Citations

This map shows the geographic impact of Knut Eis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Knut Eis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Knut Eis more than expected).

Fields of papers citing papers by Knut Eis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Knut Eis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Knut Eis. The network helps show where Knut Eis may publish in the future.

Co-authorship network of co-authors of Knut Eis

This figure shows the co-authorship network connecting the top 25 collaborators of Knut Eis. A scholar is included among the top collaborators of Knut Eis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Knut Eis. Knut Eis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Siegel, Franziska, Stephan Siegel, Gizem Karsli-Uzunbas, et al.. (2022). BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC. European Journal of Cancer. 174. S9–S10. 6 indexed citations
2.
Orsi, Douglas L., Elisabeth Pook, Anders Friberg, et al.. (2022). Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069. Journal of Medicinal Chemistry. 65(21). 14843–14863. 9 indexed citations
3.
Mortier, Jérémie, Anders Friberg, Volker Badock, et al.. (2020). Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C. ChemMedChem. 15(10). 827–832. 22 indexed citations
4.
Lewis, Timothy A., Luc de Waal, Xiaoyun Wu, et al.. (2018). Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells. Cancer Research. 78(13_Supplement). 5880–5880. 1 indexed citations
5.
Siegel, Franziska, Antje M. Wengner, Claudia Lange, et al.. (2017). BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity. Cancer Letters. 390. 21–29. 48 indexed citations
6.
Siegel, Franziska, Antje M. Wengner, Claudia Lange, et al.. (2016). Abstract 341: Preclinical mode of action and anti-tumor efficacy of the selective MKNK1 inhibitor BAY 1143269 in NSCLC models. Cancer Research. 76(14_Supplement). 341–341. 1 indexed citations
7.
Siegel, Franziska, Claudia Schneider, Ulf Boemer, et al.. (2015). Abstract 2604: Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269]. Cancer Research. 75(15_Supplement). 2604–2604. 3 indexed citations
8.
Scholz, Arne, Ulrich Lücking, Gerhard Siemeister, et al.. (2014). Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. Cancer Research. 74(19_Supplement). 4538–4538. 1 indexed citations
9.
Santamaría, Anna, Rüdiger Neef, Uwe Eberspächer, et al.. (2007). Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis. Molecular Biology of the Cell. 18(10). 4024–4036. 161 indexed citations
10.
Koppitz, Marcus & Knut Eis. (2006). Automated medicinal chemistry. Drug Discovery Today. 11(11-12). 561–568. 23 indexed citations
11.
Eis, Knut, et al.. (2005). Kinase Data Mining: Dealing with the Information (Over‐)Flow. ChemBioChem. 6(3). 567–570. 1 indexed citations
12.
Kranich, Remo, Knut Eis, Oliver Geis, et al.. (2000). A Modular Approach to Structurally Diverse Bidentate Chelate Ligands for Transition Metal Catalysis. Chemistry - A European Journal. 6(15). 2874–2894. 75 indexed citations
13.
Eis, Knut & Hans‐Günther Schmalz. (1997). Synthesis of (E,E,E)-(1,2,3,4-13C4)-Geranylgeraniol. Synthesis. 1997(2). 202–206. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alan Futran Breakdown of academic impact, for papers by Mark Charles Breakdown of academic impact, for papers by Takashi Yoshizumi Breakdown of academic impact, for papers by Sarah James Breakdown of academic impact, for papers by Erik Klapproth Breakdown of academic impact, for papers by Lars Wortmann Breakdown of academic impact, for papers by Baptiste Ronan Breakdown of academic impact, for papers by Helena Posteri Breakdown of academic impact, for papers by Manisha Das Breakdown of academic impact, for papers by Peter F. Bousquet
Rankless by CCL
2026